REGISTERED NUMBER: 12593299 (England and Wales)

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2026

FOR

DECIPHERA PHARMACEUTICALS (UK) LIMITED

Page

Company information

1

Balance sheet

2

Notes to the financial statements

3

Director:

M Ostrovsky

Registered office:

Suite 2, Ground Floor

Templeback, 10 Temple Back

Bristol

United Kingdom

BS1 6FL

Registered number:

12593299 (England and Wales)

Auditors:

Hayvenhursts Limited

Fairway House

Links Business Park

St Mellons

Cardiff

CF3 0LT

FIXED ASSETS

Investments

4

5

5

CURRENT ASSETS

Debtors

5

8,420

7,919

Cash at bank

782,306

162,300

790,726

170,219

CREDITORS

Amounts falling due within one year

6

(791,130

)

(174,103

)

NET CURRENT LIABILITIES

(404

)

(3,884

)

TOTAL ASSETS LESS CURRENT LIABILITIES

(399

)

(3,879

)

CAPITAL AND RESERVES

Called up share capital

2

2

Share premium

4

4

Retained earnings

(405

)

(3,885

)

SHAREHOLDERS' FUNDS

(399

)

(3,879

)

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 8 September 2026 and were signed by:

M Ostrovsky - Director

1.	STATUTORY INFORMATION

Deciphera Pharmaceuticals (UK) Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The Company's functional and presentational currency is pound sterling (£) and the financial statements have been rounded to the nearest pound (£).

The financial statements have been prepared for the period 1 April 2025 to 31 March 2026. In the previous period the financial accounting period has been extended to align with the fiscal year of its new parent, along with practical considerations regarding the process for implementing that change. As a result the comparative amounts presented are not entirely comparable.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements

The financial statements contain information about Deciphera Pharmaceuticals (UK) Limited as an individual Company and do not contain consolidated financial information as the parent of a group. The Company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Related party exemption

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

Turnover

Turnover represents amounts charged to the Company's parent under an agreement for marketing and other services provided, excluding value added tax. Turnover is recognised when chargeable costs are incurred. The subcontracting, third-party or foreign exchange costs incurred by the Company in the provision of the services are passed through the Company's parent without applying any mark-up.

Investments in subsidiaries

Investments in subsidiary undertakings are recognised at cost less any provision for impairment.

Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into.

Basic financial liabilities

Basic financial liabilities, including creditors, and loans from fellow group companies are initially recognised at transaction price.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are initially recognised at transaction price.

Taxation

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2025 - 3 ) .

4.	FIXED ASSET INVESTMENTS

Shares in

group

undertakings

£

Cost

At 1 April 2025

and 31 March 2026

5

Net book value

At 31 March 2026

5

At 31 March 2025

5

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

£

Other debtors

8,420

7,919

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026

2025

£

£

Trade creditors

2,892

8,758

Amounts owed to group undertakings

482,076

104,607

Taxation and social security

40,717

8,919

Other creditors

265,445

51,819

791,130

174,103

7.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the auditors was unqualified.

Gareth R Williams (Senior Statutory Auditor)

for and on behalf of Hayvenhursts Limited

8.	ULTIMATE PARENT COMPANY

The immediate parent is Deciphera Pharmaceuticals (Netherlands) B.V., a company incorporated in the Netherlands.

Ono Pharmaceutical Co., Ltd (incorporated in Japan) is regarded by the directors as being the company's ultimate parent company.

The largest and smallest group in which the results of the company are consolidated is headed by Ono Pharmaceutical Co., Ltd, incorporated in Japan. Consolidated financial statements for Ono Pharmaceutical Co., Ltd, are available on the company website www.ono-pharma.com.